Clinical Trials Logo

Behçet Disease clinical trials

View clinical trials related to Behçet Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04386824 Completed - Clinical trials for Erectile Dysfunction

Erectile Dysfunction in Patients With Non Ocular Behçet's Disease

Start date: June 15, 2019
Phase:
Study type: Observational

It was aimed to demonstrate whether erectile dysfunction is affected by BH pathogenesis and whether there is a relationship between erectile dysfunction and BD pathogenesis by assessing both sexual function and retinal micro-vascular blood flow in BH which may involve vessels from all calibrations and nature.

NCT ID: NCT04376411 Completed - Behcet Disease Clinical Trials

Role of Regulatory B Cells in Behçet's Disease

Start date: December 15, 2018
Phase:
Study type: Observational

There are limited data about the role of regulatory B cells in Behcet Disease. In this study we aimed to identify the proportions of total B lymphocytes and their regulatory subset in different Behcet Disease phenotype and therapies concentrating on the cardiovascular system attempting to unravel their function in Behcet Disease.

NCT ID: NCT03209219 Completed - Uveitis Clinical Trials

Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis

Start date: June 30, 2017
Phase: Phase 3
Study type: Interventional

Brief summary: This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral glucocorticosteroid in patients with refractory Behçet's uveitis (BDU). Half of the participants will receive IFNα2a while the other half will receive CsA.

NCT ID: NCT02756650 Completed - Behcet Disease Clinical Trials

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

Behcet
Start date: June 23, 2016
Phase: Phase 2
Study type: Interventional

Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the clinical and inflammatory findings of Behced Disease patients with neurologic and vascular involvement.

NCT ID: NCT02648581 Completed - Behçet Disease Clinical Trials

Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease

STELABEC
Start date: June 14, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the proof of concept of efficacy of ustekinumab in subjects with Behçet disease, including patients with oral ulcers (STELABEC-1) and patients with active posterior uveitis or panuveitis (STELABEC-2)

NCT ID: NCT02505568 Completed - Behcet Disease Clinical Trials

A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease

BEGIN
Start date: July 22, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of infliximab in induction regimen by assessing the mean decrease in Disease Activity Index for intestinal Behcet's disease (DAIBD) score of 20 or more in participants with active intestinal Behcet's disease who are refractory to conventional therapies.

NCT ID: NCT00995709 Completed - Behcet Disease Clinical Trials

Phase III Study in Refractory Behcet's Disease

SHIELD
Start date: October 2009
Phase: Phase 3
Study type: Interventional

The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.

NCT ID: NCT00483184 Completed - Behcet Syndrome Clinical Trials

Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of natural human interferon alpha (IFN alpha) on size, number, incidence and pain of oral ulcers associated with Behçet's Disease (BD).